TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25488084

Group type: EXPERIMENTAL
Intervention: Vacuum extractor
Number of subjects: 228

Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 228
Study: 22338102

Group type: EXPERIMENTAL
Intervention: Group-based lifestyle intervention program (six sessions)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Wait control group
Number of subjects: 307
Study: 19237657

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 20506
Study: 17171458

Group type: EXPERIMENTAL
Intervention: Intensive behavioral day treatment plus housing contingent on drug abstinence
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Intensive behavioral day treatment plus housing not contingent on abstinence
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Intensive behavioral day treatment plus no housing
Number of subjects: 138
Study: 15080765

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine solution 32 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine tablet 16 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone tablet 16/4 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine solution (all doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 16 mg tablet with naloxone
Number of subjects: 20
Study: 11136142

Group type: EXPERIMENTAL
Intervention: Esmolol (2 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lidocaine (2 mg/kg)
Number of subjects: 30
Study: 9685762

Group type: EXPERIMENTAL
Intervention: 0.05 percent sodium fluoride and 0.12 percent chlorhexidine rinses, daily from the end of the sixth month of pregnancy until delivery
Number of subjects: 0
Study: 7988301

Group type: EXPERIMENTAL
Intervention: 3.5 mg M1 intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3.5 mg M2 intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3.5 mg glibenclamide (Gb) intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3.5 mg glibenclamide (Gb) orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 8
Study: 3058290

Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose 3.34 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Desipramine (mean daily dose 192 mg)
Number of subjects: 52
Study: 31693069

Group type: EXPERIMENTAL
Intervention: Train-the-trainer condition
Number of subjects: 184

Group type: COMPARATOR
Intervention: Expert condition
Number of subjects: 184

Group type: COMPARATOR
Intervention: Comparison between Train-the-trainer and Expert conditions
Number of subjects: 184
Study: 30908711

Group type: EXPERIMENTAL
Intervention: Hepaticogastrostomy (HGS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Choledochoduodenostomy (CDS)
Number of subjects: 47
Study: 29174961

Group type: EXPERIMENTAL
Intervention: Butorphanol (0.4 mg kg−1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methadone (0.3 mg kg−1)
Number of subjects: 20
Study: 25555532

Group type: EXPERIMENTAL
Intervention: WF‐LASIK
Number of subjects: 40

Group type: COMPARATOR
Intervention: WF‐PRK
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 23841572

Group type: EXPERIMENTAL
Intervention: Plant stanol esters (staest) - 3.0 g of plant stanols/d
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group - rapeseed oil‐based spread without staest
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Plant stanol esters (staest)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 20407392

Group type: EXPERIMENTAL
Intervention: Educational and behavioral interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20016688

Group type: EXPERIMENTAL
Intervention: Granitic sand surfacing
Number of subjects: 15074

Group type: COMPARATOR
Intervention: Engineered wood fibre surfacing (Fibar)
Number of subjects: 15074

Group type: EXPERIMENTAL
Intervention: Granitic sand surfacing (all schools)
Number of subjects: 15074

Group type: COMPARATOR
Intervention: Engineered wood fibre surfacing (Fibar) (all schools)
Number of subjects: 15074
Study: 17679633

Group type: EXPERIMENTAL
Intervention: Problem-solving treatment (n = 105)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual care (n = 101)
Number of subjects: 206
Study: 15086170

Group type: EXPERIMENTAL
Intervention: Endoscopic clipping
Number of subjects: 61

Group type: COMPARATOR
Intervention: Polidocanol injection therapy
Number of subjects: 61
Study: 12438291

Group type: EXPERIMENTAL
Intervention: Darusentan 30 mg/d
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Darusentan 100 mg/d
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Darusentan 300 mg/d
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 10520920

Group type: EXPERIMENTAL
Intervention: Blue dye alone (B)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Blue dye plus radioactivity (B+R)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Needle localization (B)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall (B and B+R combined)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Surgeon experience
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Factors influencing SN identification
Number of subjects: 92
Study: 7574459

Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta‐1b (alternate-day injections)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 2251340

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6990950

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl 0.125 mg
Number of subjects: 40
Study: 31929100

Group type: EXPERIMENTAL
Intervention: CAVI (balloon-expandable transcatheter valve into the inferior vena cava)
Number of subjects: 28

Group type: COMPARATOR
Intervention: OMT (optimal medical therapy)
Number of subjects: 28
Study: 30414864

Group type: EXPERIMENTAL
Intervention: NGM282 1 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: NGM282 3 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: NGM282
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 28954530

Group type: EXPERIMENTAL
Intervention: software-supplemented e-Parenting Program (ePP)
Number of subjects: 413

Group type: COMPARATOR
Intervention: services as usual (SAU)
Number of subjects: 413

Group type: COMPARATOR
Intervention: community referral conditions
Number of subjects: 413
Study: 26131781

Group type: EXPERIMENTAL
Intervention: Sling group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonsling group
Number of subjects: 60
Study: 24803435

Group type: EXPERIMENTAL
Intervention: Polymer-free paclitaxel-eluting stent (PF‐PES)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stent (PB‐PES)
Number of subjects: 164
Study: 22537028

Group type: EXPERIMENTAL
Intervention: Unstructured, moderate to vigorous, before-school physical activity program (12 weeks, 3 days a week, 7:30-8:15 a.m.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unstructured, moderate to vigorous, before-school physical activity program
Number of subjects: 0
Study: 19692630

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg daily, step-up fashion for 8 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose insulin administration during clamp
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 8
Study: 17302186

Group type: EXPERIMENTAL
Intervention: Carotenoid mixture
Number of subjects: 2

Group type: COMPARATOR
Intervention: Antisymptomatic treatment alone
Number of subjects: 2
Study: 15712725

Group type: EXPERIMENTAL
Intervention: Diffuse reflectance spectroscopy after myringotomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diffuse reflectance spectroscopy
Number of subjects: 30
Study: 11133370

Group type: EXPERIMENTAL
Intervention: efavirenz (600 mg every 24 h) plus indinavir (1000 mg every 8 h)
Number of subjects: 327

Group type: COMPARATOR
Intervention: placebo (every 24 h) plus indinavir (800 mg every 8 h)
Number of subjects: 327
Study: 9033248

Group type: EXPERIMENTAL
Intervention: Cytobrush combined with colposcopically directed biopsies
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Endocervical curettage combined with colposcopically directed biopsies
Number of subjects: 180

Group type: COMPARATOR
Intervention: Endocervical curettage
Number of subjects: 180
Study: 8117053

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg + Hydrochlorothiazide 12.5 mg (L/HCTZ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + Hydrochlorothiazide 25 mg (C/HCTZ)
Number of subjects: 20
Study: 2942416

Group type: EXPERIMENTAL
Intervention: 0.2 mg ipratropium powder
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 mg ipratropium powder
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 mg ipratropium powder
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30875607

Group type: EXPERIMENTAL
Intervention: FMS training (eight weekly 40-min sessions)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: FMS training (DCD-FMS group)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional physical education lessons (control group)
Number of subjects: 131
Study: 28935268

Group type: EXPERIMENTAL
Intervention: Cortisol (20mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26343743

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTi) followed by Cognitive Processing Therapy (CPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control followed by Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study: 24229753

Group type: EXPERIMENTAL
Intervention: olanzapine plus sertraline
Number of subjects: 259

Group type: COMPARATOR
Intervention: olanzapine plus placebo
Number of subjects: 259
Study: 21557757

Group type: EXPERIMENTAL
Intervention: Ribose cross-linked collagen membranes (RCLM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-cross-linked membranes (Control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 19520908

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg twice a day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tadalafil 10 mg twice a day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17563395

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/d)
Number of subjects: 979

Group type: COMPARATOR
Intervention: Tamoxifen (20 or 30 mg/d)
Number of subjects: 979
Study: 15060689

Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone (50 mg/kg, not exceeding 1 g)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 10-day course of amoxicillin-clavulanate (45 mg/kg/day, in 3 divided doses)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 110
Study: 11574373

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.0625% bupivacaine with fentanyl (3 microg/mL)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Preservative‐free saline infusion
Number of subjects: 51
Study: 9562227

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (250 ml)
Number of subjects: 8
Study: 7826431

Group type: EXPERIMENTAL
Intervention: Music by J. Strauss
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Music by H. W. Henze
Number of subjects: 20
Study: 2969860

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA, 50 mg/day orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D‐Trp6 LHRH (3 mg i.m. once a month)
Number of subjects: 10

Group type: COMPARATOR
Intervention: LHRH-A
Number of subjects: 10
Study: 1969436

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine detergent solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% triclosan detergent solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: non-medicated soap
Number of subjects: 20
Study: 138480

Group type: EXPERIMENTAL
Intervention: 5-FUDR via hepatic artery infusion (HAI)
Number of subjects: 21
Study: 31641831

Group type: EXPERIMENTAL
Intervention: Public responsibility message
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Media responsibility message
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 448
Study: 31432915

Group type: EXPERIMENTAL
Intervention: Discharge guidance and telephone follow-up intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 201
Study: 27760884

Group type: EXPERIMENTAL
Intervention: 15-caliber coils
Number of subjects: 70

Group type: COMPARATOR
Intervention: 10-caliber coils
Number of subjects: 70
Study: 26305054

Group type: EXPERIMENTAL
Intervention: Kinesio taping applied over the deltoid muscle with tension
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sham (Kinesio taping applied over deltoid without tension)
Number of subjects: 24
Study: 22572414

Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS) to the left intraparietal sulcus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theta-burst stimulation (TBS) to the right parietal region
Number of subjects: 0
Study: 21649590

Group type: EXPERIMENTAL
Intervention: Extended release nicotinic acid 1500 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 60
Study: 19347385

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Combination of Telmisartan and Ramipril
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Subjects with a history of coronary artery disease or myocardial infarction
Number of subjects: 368
Study: 17050586

Group type: EXPERIMENTAL
Intervention: Azimilide 75 mg/day
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg/day
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 14692888

Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: Urinary Tract Infection (UTI)
Number of subjects: 1455
Study: 11558483

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (1 hour in 100% oxygen at 1.75 ATA)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Slightly pressurised room air (1 hour at 1.3 ATA)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 111

Group type: COMPARATOR
Intervention: Slightly pressurised room air
Number of subjects: 111
Study: 9025012

Group type: EXPERIMENTAL
Intervention: Inpatient treatment for metabolic control
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 20
Study: 8337029

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine
Number of subjects: 10317

Group type: COMPARATOR
Intervention: Hepatitis B control vaccine
Number of subjects: 10317
Study: 3773141

Group type: EXPERIMENTAL
Intervention: High Poly diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: AHA phase I diet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AHA phase III diet
Number of subjects: 9
Study: 28958023

Group type: EXPERIMENTAL
Intervention: Self-report indices SR-1/4MILE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report indices SR-BLOCKS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective MMD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report indices SR-STAIRS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of SR-STAIRS with SR-1/4MILE or SR-BLOCKS
Number of subjects: 0
Study: 29076219

Group type: EXPERIMENTAL
Intervention: CaCl2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (ZG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CaCl2 + ZG
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All treatments (CaCl2, ZG, CaCl2 + ZG, Saline)
Number of subjects: 40
Study: 26288364

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1444
Study: 24128148

Group type: EXPERIMENTAL
Intervention: Patients receiving methadone‐maintenance treatment for opioid dependence
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study: 21419395

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (Group I)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Observation only (Group II)
Number of subjects: 176
Study: 17936278

Group type: EXPERIMENTAL
Intervention: Determination of P(ET)CO(2) once daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Administration of E(2) or P
Number of subjects: 160
Study: 16310886

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 on days 1 and 8 + Carboplatin AUC 6 mg/(mLmin) on day 1 (GC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vinorelbine 30 mg/m2 weekly + Cisplatin 80 mg/m2 on day 1 (VP)
Number of subjects: 100
Study: 12024077

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (Group EA)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia integrated with mild general anaesthesia (IA)
Number of subjects: 210

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 210
Study: 10375806

Group type: COMPARATOR
Intervention: Ciclosporin (Cic) 100 mg alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ciclosporin (Cic) 100 mg with Simvastatin (Sim) 10 mg
Number of subjects: 7
Study: 7818264

Group type: EXPERIMENTAL
Intervention: Selegiline plus L-dopa-carbidopa
Number of subjects: 82

Group type: COMPARATOR
Intervention: L-dopa-carbidopa alone
Number of subjects: 82
Study: 2269136

Group type: EXPERIMENTAL
Intervention: Recall interval of three months for patients with partial dentures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive aftercare
Number of subjects: 0
Study: 346488

Group type: EXPERIMENTAL
Intervention: E. coli H‐10407 (CFA-positive strain) at a dose of 1 X 10(8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: E. coli H‐10407‐P (CFA-negative strain) at a dose of 1 X 10(8)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: E. coli H‐10407 (CFA-positive strain)
Number of subjects: 13

Group type: COMPARATOR
Intervention: E. coli H‐10407‐P (CFA-negative strain)
Number of subjects: 13
Study: 29941505

Group type: EXPERIMENTAL
Intervention: Minimally invasive perventricular closure
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard open surgical closure
Number of subjects: 200
Study: 26886210

Group type: EXPERIMENTAL
Intervention: Cigarettes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High dose e-cigarettes
Number of subjects: 27
Study: 25214238

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 (via EORTC-8D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-36v2 (via SF-6D)
Number of subjects: 0
Study: 22744651

Group type: EXPERIMENTAL
Intervention: A0001 (α‐tocopheryl quinone; EPI‐A0001)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 20211530

Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg) administered 1h before retention testing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17337198

Group type: EXPERIMENTAL
Intervention: Mini-bypass (Dideco ECC.O)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional system (Dideco 903 Avant)
Number of subjects: 60
Study: 15698525

Group type: EXPERIMENTAL
Intervention: Transurethral vaporisation of the prostate (TUVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TUVP
Number of subjects: 0

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TURP and TUVP
Number of subjects: 0
Study: 12174030

Group type: EXPERIMENTAL
Intervention: 32 mg intravenous methylprednisolone in the morning
Number of subjects: 8

Group type: COMPARATOR
Intervention: 16 mg intravenous methylprednisolone in the morning and 16 mg in the evening
Number of subjects: 8
Study: 9651462

Group type: EXPERIMENTAL
Intervention: Hyperpronation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Supination
Number of subjects: 90

Group type: COMPARATOR
Intervention: Crossover from Supination to Hyperpronation
Number of subjects: 90
Study: 7843746

Group type: EXPERIMENTAL
Intervention: TCV‐116 (4 mg PO daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: TCV‐116 (1, 2, or 4 mg PO daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 1977012

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) insertion
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tracheal tube (ETT) insertion
Number of subjects: 110
Study: 418637

Group type: EXPERIMENTAL
Intervention: Single contrast upper gastrointestinal radiography
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Double contrast upper gastrointestinal radiography
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of single and double contrast examinations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endoscopy
Number of subjects: 100
Study: 31954847

Group type: EXPERIMENTAL
Intervention: Hypoenergetic feeding (12.5-15 kcal•kg‐1•d‐1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Euenergetic feeding (25-30 kcal•kg‐1•d‐1)
Number of subjects: 83
Study: 31063679

Group type: EXPERIMENTAL
Intervention: Extended antibiotics (72 hours of perioperative antibiotics)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intraoperative antibiotics only (short antibiotics)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 27252076

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40